



Article

Supplementary Material: Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents

Gwang-Seok Yoon, Sun-Hwa Kim, Si-Hyuck Kang, Chang-Hwan Yoon, Young-Seok Cho, Tae-Jin Youn and In-Ho Chae

Table S1. Definitions of co-morbidities and clinical outcomes.

Diagnosis	Definition(ICD-10Codes)	DiagnosticDefinition
Hypertension	I10	Essential(primary)hypertension
	I11	Hypertensiveheartdisease
	I12	Hypertensiverenaldisease
	I13	Hypertensiveheartandrenaldisease
	I15	Secondaryhypertension
Diabetesmellitus	E11	Type2diabetesmellitus
	E12	Malnutrition-relateddiabetesmellitus
	E13	Otherspecifieddiabetesmellitus
	E14	Unspecifieddiabetesmellitus
Dyslipidemia	E78	Disordersoflipoproteinmetabolismandotherlipidemias
Ischemicheartdisease	I20	Anginapectoris
	I21	Acutemyocardialinfarction
	I22	Subsequentmyocardialinfarction
	I23	Certaincurrentcomplicationsfollowingacutemyocardialinfarction
	I24	Otheracuteischemicheartdiseases
	I25	Chronicischemicheartdisease
Myocardialinfarction	I21	Acutemyocardialinfarction
	I23	Certaincurrentcomplicationsfollowingacutemyocardialinfarction
Peripheralarterydisease	I70	Atherosclerosis
	I73	Otherperipheralvascular diseases
Stroke	I60	Subarachnoidhemorrhage
	I61	Intracerebralhemorrhage
	I62	Othernontraumaticintracranialhemorrhage
	I63	Cerebralinfarction
	I64	Stroke,notspecifiedashemorrhageorinfarction
Heartfailure	I50	Heartfailure
Atrialfibrillation	I480	Paroxysmalatrialfibrillation
	I481	Persistentatrialfibrillation
	I482	Chronicatrialfibrillation
	I483	Typicalatrialfutter
	I484	Atypicalatrialfutter
	I489	Unspecifiedatrialfibrillationandatrialfutter
Majorbleeding		Intracranialbleeding
		Gastrointestinalbleeding
		Otherbleeding

CT, computer tomography; ICD, international classification of disease; ICH, intracerebral hemorrhage; MRI, magnetic resonance imaging; PCI, percutaneous coronary intervention; RBC, red blood cell.

Table S2. Baseline characteristics of patients who were treated with OAC monotherapy versus OAC with SAPT in total study and weighted study populations.

Variables	Overall Cohort				IPTW Cohort				Standardized Difference
	Total	OAC Monotherapy	OAC with SAPT	<i>p</i> Value	Total	OAC Monotherapy	OAC with SAPT	<i>p</i> -Value	
Age, years	71.2 ± 9.1	72.3 ± 8.4	71.0 ± 9.2	<.001	71.5 ± 8.8	71.9 ± 8.3	71.2 ± 9.1	0.403	0.078
Male, n (%)	688 (67.6)	77 (55.8)	611 (69.5)	0.002	1264.8 (67.0)	576 (65.9)	688 (68.0)	0.634	0.044
Baseline risk factors									
Hypertension	922 (90.6)	125 (90.5)	797 (90.6)	>.999	1709 (90.6)	791 (90.5)	918 (90.7)	0.934	0.088
Diabetes mellitus	361 (35.5)	49 (35.5)	312 (35.4)	>.999	633(35.2)	302 (34.5)	361 (35.7)	0.797	0.025
Renal disease	82 (8.0)	12 (8.7)	70 (7.9)	0.900	156 (35.7)	75 (8.6)	81 (8.0)	0.812	0.023
Dyslipidemia	981 (96.4)	133 (96.3)	848 (96.4)	>.999	1827 (96.9)	851 (97.4)	976 (96.4)	0.530	0.050
Ischemic heart disease	1014 (99.7)	137 (99.2)	877 (99.7)	0.875	1875 (99.4)	866 (99.0)	1009 (99.7)	0.239	0.138
Prior myocardial infarction	403 (39.6)	45 (32.6)	358 (40.7)	0.086	706 (67.4)	302 (34.6)	404 (39.9)	0.271	0.109
Peripheral artery disease	268 (26.3)	41 (29.7)	227 (25.8)	0.390	493 (26.1)	228 (26.1)	265 (26.1)	0.988	0.001
Prior stroke	427 (41.9)	67 (48.5)	360 (40.9)	0.112	812 (43.1)	391 (44.8)	241 (41.6)	0.502	0.065
Heart failure	654 (64.3)	92 (66.6)	562 (63.9)	0.598	1211 (64.2)	562 (64.3)	649 (64.2)	0.982	0.002
Liver disease	23 (2.2)	6 (4.3)	17 (1.9)	0.143	42 (2.2)	21 (2.4)	21 (2.1)	0.783	0.021
Atrial fibrillation	915 (89.9)	120 (86.9)	795 (90.4)	0.265	1705 (90.4)	791 (90.5)	913 (90.2)	0.906	0.010
CHA ₂ DS ₂ -VASc score	5.2 (1.8)	5.6 (1.8)	5.2 (1.7)	<.001	5.3 (1.8)	5.3 (1.8)	5.2 (1.8)	0.983	0.003

IPTW, Inverse Probability Treatment Weighting; OAC, oral anticoagulant; SAPT, single antiplatelet therapy.